Moderna Announces Prelim. Trial Data For COVID-19 Vaccine Showing Effectiveness Against EG.5 And FL.1.5.1 Variants
Portfolio Pulse from Benzinga Newsdesk
Moderna has announced preliminary trial data for its COVID-19 vaccine, indicating effectiveness against the EG.5 and FL.1.5.1 variants. This could potentially boost the company's stock in the short term.
August 17, 2023 | 8:18 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Moderna's COVID-19 vaccine has shown effectiveness against new variants in preliminary trial data. This could potentially boost the company's stock in the short term.
The announcement of positive preliminary trial data for Moderna's COVID-19 vaccine against new variants is a significant development. This could potentially increase demand for the vaccine, leading to increased revenues and a potential boost in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100